AbolerIS Pharma is a Belgian biopharmaceutical company developing a novel approach to the treatment of chronic autoimmune and inflammatory diseases.
About
The AbolerIS team is composed of scientific founders with decades of experience in basic and translational immunology and a strong leadership team with experienced biotech leaders and clinical experts.
AbolerIS Pharma aims to develop molecules that regulate immune responses with high selectivity with a long efficacy.
AbolerIS Pharma is developing a first-in-class monoclonal antibody based on a novel scientific approach to restore the balance in the immune system. Our novel and unique therapeutic approaches induce immune tolerance and preserve useful immune responses in inflammatory, autoimmune, and degenerative diseases.
AbolerIS Pharma aims to develop molecules that regulate immune responses with high selectivity with a long efficacy.
AbolerIS Pharma is developing a first-in-class monoclonal antibody based on a novel scientific approach to restore the balance in the immune system. Our novel and unique therapeutic approaches induce immune tolerance and preserve useful immune responses in inflammatory, autoimmune, and degenerative diseases.
